Bcr-Abl
Bcr-Abl tyrosine-kinase inhibitors (TKI) are the first-line therapy for most patients with chronic myelogenous leukemia (CML). More than 90% of CML cases are caused by a chromosomal abnormality that results in the formation of a so-called Philadelphia chromosome. This abnormality is a consequence of fusion between the Abelson (Abl) tyrosine kinase gene at chromosome 9 and the break point cluster (Bcr) gene at chromosome 22, resulting in a chimeric oncogene (Bcr-Abl) and a constitutively active Bcr-Abl tyrosine kinase that has been implicated in the pathogenesis of CML. Compounds have been developed to selectively inhibit the tyrosine kinase.
Bcr-Abl Isoform Specific Products
All Product Categories
-
Bcr-Abl Inhibitors
(208)
View all products
-
Bcr-Abl Antagonist
(1)
View all products
-
Bcr-Abl Activator
(1)
View all products
-
Bcr-Abl Modulators
(2)
View all products
-
Bcr-Abl Degraders
(23)
View all products
-
Bcr-Abl Control
(1)
View all products
-
Bcr-Abl Substrate
(1)
View all products
-
Bcr-Abl Ligand
(1)
View all products
-
ABL1 Proteins
(8)
View all products
-
Bcr-Abl Related Products (257)
Related Products (257)
-
Recombinant Proteins (8)
-
Antibodies (6)
-
Bcr-Abl Isoform Comparison
-
HG-7-85-01-NH2
0 ImagesHG-7-85-01-NH2 is the HG-7-85-01 (ABL inhibitor) based moiety, binds to IAP ligand via a linker to form SNIPER.
-
SNIPER(ABL)-020
0 ImagesSNIPER(ABL)-020, conjugating Dasatinib (ABL inhibitor) to Bestatin (IAP ligand) with a linker, induces the reduction of BCR-ABL protein.
-
BCR-ABL-IN-8
0 ImagesCat. No.: HY-156148CAS No.: 1808288-49-4BCR-ABL-IN-8 (compound 26f) is a BCR-ABL inhibitor containing trimethoxy group.
-
DB07107
0 ImagesCat. No.: HY-123390CAS No.: 552332-71-5
-
Abl Cytosolic Substrate
0 ImagesSynonyms: Abltide
-
Dasatinib (GMP)
0 ImagesCat. No.: HY-10181GCAS No.: 302962-49-8Synonyms: BMS-354825 (GMP)Dasatinib (BMS-354825) (GMP) is a GMP-grade Dasatinib (HY-10181). GMP-grade small molecules can be used as adjuvant agents in cell therapy. Dasatinib (BMS-354825) is an orally active, ATP-competitive, dual Src/Bcr-Abl inhibitor with potent antitumor activity. The Ki values for Src and Bcr-Abl are 16 pM and 30 pM, respectively. Dasatinib inhibits Bcr-Abl and Src with IC50 values of less than 1.0 nM and 0.5 nM, respectively. Dasatinib also induces apoptosis and autophagy.
-
PROTAC BCR-ABL1 ligand 1
0 ImagesPROTAC BCR-ABL1 ligand 1, compound GMB-475, is the ligand of PROTAC that allosterically targets BCR-ABL1 protein and recruits the E3 ligase Von Hippel-Lindau, resulting in ubiquitination and subsequent degradation of BCR-ABL1.
-
Imatinib-d3 hydrochloride
0 ImagesCat. No.: HY-15463S2CAS No.: 1134803-18-1Synonyms: STI571-d3 hydrochloride; CGP-57148B-d3 hydrochlorideImatinib-d3 (hydrochloride) is the deuterium labeled Imatinib. Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively. Imatinib also is an inhibitor of SARS-CoV and MERS-CoV.
-
Imatinib Mesylate (Standard)
0 ImagesSynonyms: STI571 Mesylate (Standard); CGP-57148B Mesylate (Standard)Imatinib (Mesylate) (Standard) is the analytical standard of Imatinib (Mesylate). This product is intended for research and analytical applications. Imatinib Mesylate (STI571 Mesylate) is an orally active tyrosine kinases inhibitor that inhibits c-Kit, Bcr-Abl, and PDGFR (IC50=100 nM) tyrosine kinases.
-
Ponatinib-d8
0 ImagesSynonyms: AP24534-d8
-
Herbimycin A
0 ImagesHerbimycin A is an antibiotic and protein tyrosine kinase inhibitor. Herbimycin A directly inhibits the autophosphorylation of p210 BCR-ABL with an IC50 of approximately 5 μM, and reduces Src kinase activity. Herbimycin A also induces the degradation of receptor tyrosine kinases such as insulin-like growth factor 1 receptor (IGF-1R), insulin receptor (IR) and epidermal growth factor receptor (EGFR) via the ubiquitin-20S proteasome pathway. Herbimycin A directly modifies NF-κB p50, with the main target site involving Cys62, thereby blocking the DNA binding of p50 and NF-κB-driven gene expression. Herbimycin A can be used in studies related to tyrosine kinase signaling, chronic myeloid leukemia, NF-κB signaling, osteoclast function, apoptosis and cellular stress.
-
Dasatinib-d4
0 ImagesCat. No.: HY-10181S1CAS No.: 1160297-08-4Synonyms: BMS-354825-d4Dasatinib-d4 (BMS-354825-d4) is deuterium labeled Dasatinib. Dasatinib (BMS-354825) is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity. The Kis are 16 pM and 30 pM for Src and Bcr-Abl, respectively. Dasatinib inhibits Bcr-Abl and Src with IC50s of <1.0 nM and 0.5 nM, respectively. Dasatinib also induces apoptosis and autophagy.
